On-label and off-label use of high-dose influenza vaccine in the United States, 2010–2012

References

• Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289(2):179–86; PMID:12517228; http://dx.doi.org/10.1001/jama.289.2.179
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Zhou X, Talbot HK, Soethout E, Bleackley RC, Granville DJ, Pawelec G. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine 2012; 30(12):2060-7; PMID:22289511; http://dx.doi.org/10.1016/j.vaccine.2012.01.015
   PubMed Web of Science ®Google Scholar
• Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine 2007; 25(16):3066-9; PMID:17275144; http://dx.doi.org/10.1016/j.vaccine.2007.01.025
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Licensure of a high-dose inactivated influenza vaccine for persons aged ≥65 years (fluzone high-dose) and guidance for use — United States, 2010. MMWR 2010; 59(16):485-6
   PubMedGoogle Scholar
• Chen WH, Cross AS, Edelman R, Sztein MB, Blackwelder WC, Pasetti MF. Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine. Vaccine 2011; 29(16):2865-73; PMID:21352939; http://dx.doi.org/10.1016/j.vaccine.2011.02.017
   PubMed Web of Science ®Google Scholar
• Jacobson R, Poland GA, Sullivan SJ. Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine. Expert Rev Vac 2010; 9:1127+; PMID:20923264; http://dx.doi.org/10.1586/erv.10.117
   PubMedGoogle Scholar
• Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200(2):172-80; PMID:19508159; http://dx.doi.org/10.1086/599790
   PubMed Web of Science ®Google Scholar
• Cate TR, Rayford Y, Niño D, Winokur P, Brady R, Belshe R, Chen W, Atmar RL, Couch RB. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010; 28(9):2076-9; PMID:20044052; http://dx.doi.org/10.1016/j.vaccine.2009.12.041
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009–2010 season. Vaccine 2013; 31(6):861-6; PMID:23261045; http://dx.doi.org/10.1016/j.vaccine.2012.12.013
   PubMed Web of Science ®Google Scholar
• Greenberg DP. Fluzone high-dose vaccine FIM12 efficacy trial summary results: ACIP meeting, October 24, 2013; Atlanta, GA: Centers for Disease Control and Prevention; 2013. Available at: http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-oct-2013/04-Fluzone-Greenberg.pdf. Accessed February 13, 2014.
   Google Scholar
• Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines - recommendations of the advisory committee on immunization practices (ACIP), 2013-2014. MMWR 2013; 62(7):1-43
   PubMedGoogle Scholar
• Keitel Wa, Atmar RL, Cate TR, Petersen NJ, Greenberg SB, Ruben F, Couch RB. SAfety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166(10):1121-7; PMID:16717175; http://dx.doi.org/10.1001/archinte.166.10.1121
   PubMedGoogle Scholar
• Couch RB, Winokur P, Brady R, Belshe R, Chen WH, Cate TR, Sigurdardottir B, Hoeper A, Graham IL, Edelman R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007; 25(44):7656-63; PMID:17913310; http://dx.doi.org/10.1016/j.vaccine.2007.08.042
   PubMed Web of Science ®Google Scholar
• Moro PL, Arana J, Cano M, Menschik D, Yue X, Lewis P, Haber P, Martin D, Broder K. Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the vaccine adverse event reporting system, 1 July 2010–31 December 2010. Clin Infect Dis 2012; 54(11):1608-14; PMID:22441652; http://dx.doi.org/10.1093/cid/cis256
   PubMed Web of Science ®Google Scholar
• Freed GL, Clark SJ, Cowan AE, Coleman MS. Primary care physician perspectives on providing adult vaccines. Vaccine 2011; 29(9):1850-4; PMID:21216314; http://dx.doi.org/10.1016/j.vaccine.2010.12.097
   PubMedGoogle Scholar
• Szilagyi PG, Shone LP, Barth R, Kouides RW, Long C, Humiston SG, Jennings J, Bennett NM. Physician practices and attitudes regarding adult immunizations. Prev Med 2005; 40(2):152-61; PMID:15533524; http://dx.doi.org/10.1016/j.ypmed.2004.05.010
   PubMedGoogle Scholar
• Hurley LP, Lindley MC, Harpaz R, Stokley S, Daley MF, Crane LA, Dong F, Beaty BL, Tan L, Babbel C, et al. Barriers to the use of herpes zoster vaccine. Ann Intern Med 2010; 152(9):555-60; PMID:20439573; http://dx.doi.org/10.7326/0003-4819-152-9-201005040-00005
   PubMed Web of Science ®Google Scholar
• Levêque D. Off-label use of anticancer drugs. Lancet Oncol 2008; 9(11):1102-7; http://dx.doi.org/10.1016/S1470-2045(08)70280-8
   PubMed Web of Science ®Google Scholar
• Maher A, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011; 306(12):1359-69; PMID:21954480; http://dx.doi.org/10.1001/jama.2011.1360
   PubMed Web of Science ®Google Scholar
• Furst DE, Fleischman R, Kalden J, Kavanaugh A, Sieper J, Mease P, Smolen J, Breedveld F. Documentation of off-label use of biologics in Rheumatoid Arthritis. Ann Rheum Dis 2013; 72(suppl 2):ii35-ii51; PMID:23532442
   PubMedGoogle Scholar
• Tseng HF, Sy LS, Qian L, Marcy SM, Jackson LA, Glanz J, Nordin J, Baxter R, Naleway A, Donahue J, et al. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population. Clin Infect Dis 2013; 56(3):315-21; PMID:23196953; http://dx.doi.org/10.1093/cid/cis871
   PubMed Web of Science ®Google Scholar
• Lu P-j, O’Halloran A, Ding H, Williams WW, Bridges CB, Kennedy ED. National and state-specific estimates of place of influenza vaccination among adult populations – United States, 2011–12 influenza season. Vaccine 2014; 32(26):3198-204; PMID:24731815; http://dx.doi.org/10.1016/j.vaccine.2014.04.003
   PubMedGoogle Scholar
• Kaiser Family Foundation. Medicare at a glance. Menlo Park, CA: Kaiser Family Foundation; 2012. Available at: http://kff.org/medicare/fact-sheet/medicare-at-a-glance-fact-sheet/. Accessed July 26, 2013.
   Google Scholar
• Umans B, Nonnemaker KL. The medicare beneficiary popoluation. Washington, DC: AARP Public Policy Institue; 2009. Available at: http://assets.aarp.org/rgcenter/health/fs149_medicare.pdf. Accessed August 1, 2014.
   Google Scholar
• Panozzo CA, Becker-Dreps S, Pate V, Jonsson Funk M, Stürmer T, Weber DJ, Brookhart MA. Patterns of rotavirus vaccine uptake and use in privately-insured US infants, 2006–2010. PLoS One 2013; 8(9):e73825; PMID:24066076; http://dx.doi.org/10.1371/journal.pone.0073825
   PubMed Web of Science ®Google Scholar
• Tsai Y, Zhou F, Wortley P, Shefer A, Stokley S. Trends and characteristics of preventive care visits among commercially insured adolescents, 2003-2010. J Pediat 2014; 164(3):625-30; PMID:24286572; http://dx.doi.org/10.1016/j.jpeds.2013.10.042
   PubMed Web of Science ®Google Scholar
• Mintzer S, Maio V, Foley K. Use of antiepileptic drugs and lipid-lowering agents in the United States. Epilepsy Behav 2014; 34(0):105-8; PMID:24735835; http://dx.doi.org/10.1016/j.yebeh.2014.03.008
   PubMedGoogle Scholar
• Mark TL, Joish VN, Hay JW, Sheehan DV, Johnston SS, Cao Z. Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs. Am J Geriatr Psychiat 2011; 19(3):211-21; PMID:21425504; http://dx.doi.org/10.1097/JGP.0b013e3181f1803d
   PubMed Web of Science ®Google Scholar